immuno-oncology
Boehringer Ingelheim acquires Nerio Therapeutics, strengthening immune-oncology profile
July 30, 2024Mergers and Acquisitions Boehringer Ingelheim, Nerio Therapeutics, Oncology, immuno-oncology, oncology
Biopharmaceutical company Boehringer Ingelheim has announced the acquisition of drug discovery and development company Nerio Therapeutics for up to $1.3bn, …
Astellas and Kelonia Therapeutics enter agreement for development of immuno-oncology therapeutics
February 16, 2024Research and Development Astellas Pharma, Kelonia Therapeutics, Oncology, collaboration, immuno-oncology
Astellas Pharma and Kelonia Therapeutics have announced that Xyphos Biosciences (a wholly owned subsidiary of Astellas) and Kelonia have entered …
MSD teams up with Harvard University to discover novel immune system pathways to fight cancer
August 13, 2019Manufacturing and Production, Research and Development Cancer, Harvard, MSD, Merck, immuno-oncology, oncology, pharma
A new partnership between MSD and Harvard University hopes to combine the expertise of both parties to carve a path …
Sobi acquire Novimmune in deal worth more than £400 million
June 13, 2019Business Services, Research and Development R&D, emapalumab, immuno-oncology, immunology, pharma
Swedish rare disease specialist Sobi has agreed to buy Swiss firm Novimmune ion a deal worth more than £400 million. …
Amgen agrees to buy Nuevolution for $167 million
May 22, 2019Research and Development Amgen, Cancer, Nuevolution, biotech, drug discovery, immuno-oncology, immunology, pharma
California biotech Amgen has agreed to buy Danish biopharmaceutical company Nuevolution AB for 1.61 billion Swedish crowns ($166.8 million). The …
Pfizer immune-oncology leader joins Aduro Biotech as new CMO
April 23, 2019Manufacturing and Production Aduro Biotech, Cancer, Pfizer, immuno-oncology, immunotherapy, oncology
Pfizer’s vice president and head of immune-oncology clinical development has joined Aduro Biotech as the company’s new Chief Medical Officer, …
Celgene signs deals with two Massachusetts-based biotechs
January 21, 2019Sales and Marketing Celgene, Kyn, Obsidian, cell therapy, immuno oncology, immuno-oncology
New Jersey-based biotechnology firm Celgene has signed deals with two Massachusetts-based biotechs: immuno-oncology specialist Kyn therapeutics and cell therapy firm …
Gilead inks $1.8 bn deal with immuno-oncology biotech Agenus
December 21, 2018Medical Communications Agenus, Gilead, Lexington, Massachusetts, USA, immuno-oncology, oncology
California-based firm Gilead Sciences and Massachusetts-based immuno-oncology biotech Agenus have announced that they have entered into a partnership focused on …
Roche acquires immuno-oncology biotech Tusk in €655m deal
October 1, 2018Sales and Marketing Droia, Roche, Tusk, immuno-oncology, immunology, oncology
Swiss multinational Roche has acquired the privately held immuno-oncology company Tusk Therapeutics in a deal that could be worth up …
MSD says Phase III trials for Keytruda to treat advanced melanoma shows better survival
June 8, 2016Research and Development ASCO, MSD, Merck & Co, PD-L1, advanced melanoma, drug trial, immuno-oncology, keytruda
Merck & Co (NYSE: MRK) said late-stage trials for its immunotherapy Keytruda (pembrolizumab) to treat advanced melanoma showed over half …
Trial data shows promise for Lilly/MSD combo regimen in lung cancer
June 6, 2016Research and Development, Sales and Marketing MSD, Merck, collaboration, immuno-oncology, lilly, lung cancer, non-small cell, parternship
Eli Lilly (NYSE: LLY) has presented data at the American Society of Clinical Oncology (ASCO) annual congress showcasing its collaborations …
Abbvie acquires immune-oncology target from argenx
April 21, 2016Research and Development, Sales and Marketing AbbVie, Protein, argenx, garp, immuno-oncology, immunosuppresive
AbbVie (NYSE:ABBV) has announced the acquisition of a new preclinical-stage human antibody program evaluating the novel immune-oncology target GARP, a …
Focus: Bristol-Myers Squibb’s wonder drug – Opdivo
April 20, 2016Research and Development, Sales and Marketing BMS, growth, immuno-oncology, opdivo, sales
By Anjali ShuklaNew data for Bristol-Myers Squibb’s (NYSE: BMY) Opdivo to treat head and neck cancer showed superior survival compared with …
Sosei‘s Heptares And Kymab to collaborate on developing new antibody therapeutics
April 18, 2016Research and Development, Sales and Marketing Heptares Therapeutics, Kymab Ltd, Sosei Group, collaboration, drug development, immuno-oncology
Japan’s Sosei Group Corp (TSE: 4565) has signed a collaboration deal with Kymab Ltd to develop and market novel antibody …
OncoMed initiates Phase Ib immuno-oncology combination clinical trial
March 18, 2016Medical Communications, Research and Development Merck, OncoMed, clinical trial, demcizumab, immuno-oncology, immuno-oncology combination, pembrolizumab, phase ib
OncoMed (NASDAQ: OMED) has announced the beginning of its Phase Ib clinical trial to investigate if the combination of demcizumab …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
